Tetrahydrocannabinol - Adverse effects
Research News and Information

Tuesday, November 24, 2009

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

30 May 2009 We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with ... Read more...

Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans.

11 May 2009 This study assessed the acute physiologic effects over time of (co)administration of Delta9-tetrahydrocannabinol (Delta9-THC) (the main psychoactive compound of cannabis) and 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in 16 healthy ... Read more...

Cannabinoids for the treatment of dementia.

13 Apr 2009 BACKGROUND: Following the discovery of an endogenous cannabinoid system and the identification of specific cannabinoid receptors in the central nervous system, much work has been done to investigate the main effects of these compounds. There is ... Read more...

Latest indexed articles for 'Tetrahydrocannabinol - Adverse effects'

These are the very latest articles for this heading:

• Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. 30 May 2009
• Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans. 11 May 2009
• Cannabinoids for the treatment of dementia. 13 Apr 2009
• Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. 30 Mar 2009
• Nicotine and Delta(9)-tetrahydrocannabinol withdrawal induce Narp in the central nucleus of the amygdala. 27 Feb 2009
• Chronic treatment with Delta(9)-tetrahydrocannabinol impairs spatial memory and reduces zif268 expression in the mouse forebrain. 30 Jan 2009
• Emerging strategies for exploiting cannabinoid receptor agonists as medicines. 30 Jan 2009
• Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. 30 Jan 2009
• Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). 18 Dec 2008
• Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. 4 Dec 2008
• Cannabis sativa smoke inhalation decreases bone filling around titanium implants: a histomorphometric study in rats. 29 Nov 2008
• What is the mechanism whereby cannabis use increases risk of psychosis? 29 Sep 2008
• Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. 4 Aug 2008
• Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. 5 Jul 2008
• Tolerability and effects of oral Delta9-tetrahydrocannabinol in older adolescents with marijuana use disorders. 24 Jun 2008
• [What sense in cannabinoid use as regulated by Italian DM 18/04/07? Pharmacological and legal considerations] 30 May 2008
• Use of dronabinol for cannabis dependence: two case reports and review. 28 Feb 2008
• The coherence of the evidence linking cannabis with psychosis. 28 Feb 2008
• Should we advise patients with serious mental illness to stop using cannabis? 28 Feb 2008
• Drawing conclusions about cannabis and psychosis. 28 Feb 2008

See a longer list of these articles.

Technical information about 'Tetrahydrocannabinol'

Definition: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. Dronabinol is a synthetic form of delta-9-THC.

Chemical name: 6H-Dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-

Registry Number: 1972-08-3

Descriptor UI: D013759

Alternative terms: Tetrahydrocannabinol; delta(1)-Tetrahydrocannabinol; THC; delta(9)-Tetrahydrocannabinol; delta(9)-THC; Dronabinol; 9-ene-Tetrahydrocannabinol; 9 ene Tetrahydrocannabinol; delta(1)-THC; Tetrahydrocannabinol, (6a-trans)-Isomer; Tetrahydrocannabinol, Trans-Isomer; Tetrahydrocannabinol, Trans Isomer; Tetrahydrocannabinol, (6aS-cis)-Isomer; Tetrahydrocannabinol, Trans-(+-)-Isomer; Marinol; Solvay Brand of Tetrahydrocannabinol; Tetrahydrocannabinol, (6aR-cis)-Isomer;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; biosynthesis;

Pharmacological Action: Hallucinogens; Psychotropic Drugs; Analgesics, Non-Narcotic;

Tree Number: D02.455.849.090.810;

History Note: 77(71); was see under CANNABIS 1975-76